MedTrace Logo

Immunisation, Treatment and Controlled Human Hookworm Infection

NCT03702530 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2019-09-04

No results posted yet for this study

Summary

24 healthy volunteers will be immunized with three times 50 L3 larvae or placebo followed by treatment with albendazol and subsequently challenged with twice 50 L3 larvae.

Conditions

  • Necator Americanus Infection

Interventions

BIOLOGICAL

3x 50 L3 larvae immunisation with albendazole treatment

Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8

OTHER

3x placebo immunisation with albendazole treatment

Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8

BIOLOGICAL

2x 50 L3 larvae infection

After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15

Sponsors & Collaborators

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • M. Roestenberg, MD, PhD · Leiden University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2019-09-02
Completion
2019-09-02

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03702530 on ClinicalTrials.gov